Location
Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Overview:
Acute Respiratory Distress Syndrome is an acute lung dysfunction, which occurs as a result of injury or illness. It is known as adult respiratory distress syndrome, it may also affect children. In this condition small air sacs (alveoli) in lungs are accumulated with fluid which makes difficulty in passing of oxygen into blood stream. Symptoms of acute respiratory distress syndrome includes difficulty in breathing, rapid breathing, hyper ventilation. ARDS can be developed into deep infection which causes pneumonia, trauma.
ARDS can be diagnosed by blood tests, chest x-rays and others. Treatment for the ARDS are mechanical ventilation, supplemental oxygen, fluid management and a technique called positive end expiratory pressure (PEEP) to help push the fluid out of air sacs, extracorporeal membrane oxygenation, human mesenchymal stem cells.
Segmentation:
By Drugs, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
By Route of Administration, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
By Trial Phase, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
By Company, Acute Respiratory Distress Syndrome pipeline drugs are segmented as:
Â
Space Analysis:
Report Description:
Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Acute Respiratory Distress Syndrome treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Acute Respiratory Distress Syndrome disease pipeline drugs development. This report studies the dynamics of the Acute Respiratory Distress Syndrome Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Acute Respiratory Distress Syndrome disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
Location
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary
Â
2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Introduction
Â
2.1. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Taxonomy
2.2. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market –Definitions
2.2.1. Drugs
2.2.2. Route of Administration
2.2.3. Trial Phase
Â
3. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics
Â
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
3.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market – Competition Landscape
3.7. Epidemiology
Â
4. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
Â
4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market opportunity analysis
Â
5. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market, By Drugs, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
5.1. Interferon Beta-1a
5.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
Â
5.2. Imatinib
5.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
Â
5.3. Sivelestat
5.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
Â
5.4. L-Citrulline
5.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
Â
5.5. Poractantalfa
5.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
Â
5.6. Ganciclovir
5.6.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
Â
5.7. Others
5.7.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
Â
6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration,2013 - 2017 and Forecast, 2017 – 2024
Â
6.1. Â Oral
6.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
Â
6.2. Parenteral
6.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
Â
7. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
7.1. Preclinical Trials
7.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Phase 1
7.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
Â
7.3. Phase 2
7.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
Â
7.4. Phase 3
7.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
Â
7.5. Phase 4
7.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
Â
8. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
8.1. North America
8.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
Â
8.2. Europe
8.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
Â
8.3. Asia-Pacific
8.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
Â
8.4. Latin America
8.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
Â
8.5. Middle East and Africa
8.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
Â
8.6. Global Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
Â
9. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
9.1. Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Interferon Beta-1a
9.1.2. Imatinib
9.1.3. Sivelestat
9.1.4. L-Citrulline
9.1.5. Poractantalfa
9.1.6. Ganciclovir
9.1.7. Others
Â
9.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
Â
9.3. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Preclinical Trials
9.3.2. Phase 1
9.3.3. Phase 2
9.3.4. Phase 3
9.3.5. Phase 4
Â
9.4. Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
Â
9.5. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
9.6. North America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
Â
10. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
10.1. Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Interferon Beta-1a
10.1.2. Imatinib
10.1.3. Sivelestat
10.1.4. L-Citrulline
10.1.5. Poractantalfa
10.1.6. Ganciclovir
10.1.7. Others
Â
10.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
Â
10.3. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Preclinical Trials
10.3.2. Phase 1
10.3.3. Phase 2
10.3.4. Phase 3
10.3.5. Phase 4
Â
10.4. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
Â
10.5. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
10.6. Europe Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
Â
11. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
11.1. Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Interferon Beta-1a
11.1.2. Imatinib
11.1.3. Sivelestat
11.1.4. L-Citrulline
11.1.5. Poractantalfa
11.1.6. Ganciclovir
11.1.7. Others
Â
11.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
Â
11.3. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Preclinical Trials
11.3.2. Phase 1
11.3.3. Phase 2
11.3.4. Phase 3
11.3.5. Phase 4
Â
11.4. Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)Â Â Â Â Â Â Â
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
Â
11.5. Asia-Pacific Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
11.6. Asia-PacificAcute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
Â
12. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2012 - 2012 - 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
12.1. Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Interferon Beta-1a
12.1.2. Imatinib
12.1.3. Sivelestat
12.1.4. L-Citrulline
12.1.5. Poractantalfa
12.1.6. Ganciclovir
12.1.7. Others
Â
12.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
Â
12.3. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Preclinical Trials
12.3.2. Phase 1
12.3.3. Phase 2
12.3.4. Phase 3
12.3.5. Phase 4
Â
12.4. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
Â
12.5. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
12.6. Latin America Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
Â
13. Middle East and Africa Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
Â
13.1. Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Interferon Beta-1a
13.1.2. Imatinib
13.1.3. Sivelestat
13.1.4. L-Citrulline
13.1.5. Poractantalfa
13.1.6. Ganciclovir
13.1.7. Others
Â
13.2. Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
Â
13.3. Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Preclinical Trials
13.3.2. Phase 1
13.3.3. Phase 2
13.3.4. Phase 3
13.3.5. Phase 4
Â
13.4. Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
Â
13.5. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase and Region, 2018 – 2024
13.6. MEA Acute Respiratory Distress Syndrome Disease Pipeline Drugs Assessment Market Dynamics – Trends
Â
14. Competition Landscape
Â
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AltorBioScience
14.2.2. Genentech, Inc.
14.2.3. Faron Pharmaceuticals Ltd.
14.2.4. AltorBioScience
14.2.5. Suntory Pharmaceutical
14.2.6. Eli Lilly and Company
14.2.7. Asklepion Pharmaceuticals, LLC
14.2.8. BioMarck Pharmaceuticals, Ltd.
14.2.9. Others
Â
15. Research Methodology
16. Key Assumptions and Acronyms